POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for blood cancer patients battling severe anemia
Disease control OngoingThis study is testing a new drug called INCB000928 to see if it can help people with a serious bone marrow cancer called myelofibrosis who have severe anemia. The drug will be tested alone and in combination with an existing medication, ruxolitinib. The main goals are to find a s…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for blood cancer patients: Two-Drug combo aims to tame disease
Disease control OngoingThis large, late-stage trial is testing whether adding a new drug called pelabresib to the standard treatment (ruxolitinib) works better for people newly diagnosed with myelofibrosis, a serious bone marrow cancer. The study will see if the combination shrinks enlarged spleens mor…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC